Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD

Thorax

Volumn 60, Issue 10, 2005, Pages 827-833

  Montuschi, P ^a,b   Macagno, F ^b   Parente, P ^b   Valente, S ^b   Lauriola, L ^b   Ciappi, G ^b   Kharitonov, S A ^c   Barnes, P J ^c   Ciabattoni, G ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; ICOSANOID; PLACEBO; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE B2;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EX VIVO STUDY; FEMALE; HUMAN; IMMUNOASSAY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BLOOD GAS ANALYSIS; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOUBLE-BLIND METHOD; EICOSANOIDS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IBUPROFEN; LACTONES; LEUKOTRIENE B4; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; SULFONES; THROMBOXANE B2; VITAL CAPACITY;

EID: 26944460816     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.035592     Document Type: Article

References (31)

1. Hill AT, Bayley D, Stockley RA. The Interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999;160:893-8.
2. Gompertz S, O'Brien C, Bayley DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-9.
3. 2. Lancet 1995;345:436-8.
4. 2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1999;159:31-6.
5. 2α reduce exhaled nitric oxide in normal and asthmatic subjects irrespective of airway caliber changes. Am J Respir Crit Care Med 1998;158:1374-8.
6. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free-radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-7.
7. Montuschi P, Barnes PJ, Roberts LJ II. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18:1791-800.
8. Montuschi P, Kharitonov SA, Ciabattoni G, et al. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58:585-8.
9. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175-7.
10. Mutlu GM, Garey KW, Rabbins RA, et al. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med 2001;164:731-7.
11. Montuschi P. Indirect monitoring of lung inflammation. Nat Rev Drug Discov 2002;1:238-42.
12. Montuschi P, Barnes PJ. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci 2002;23:232-7.
13. 2 in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:A908.
14. Montuschi P, Barnes PJ. Exhaled leukotrienes and prostaglandins in asthma. J Allergy Clin Immunol 2002;109:615-20.
15. National Heart, Lung, and Blood Institute. Global initiative for chronic obstructive lung disease, NHLBI/WHO Workshop Report. Publication No 2701. Bethesda, MD: National Institute of Health, 2001 (updated 2003).
16. 4 measurements in exhaled breath condensate. Inflamm Res 2003;52:69-73.
17. 2 measurements in exhaled breath condensate. Inflamm Res 2003;52:502-6.
18. Nightingale JA, Rogers DF, Hart LA, et al. Effect of inhaled endotoxin on induced sputum in normal atopic and atopic asthmatic subjects. Thorax 1998;53:563-71.
19. Zimmerman RL, Montone KT, Fogt F, et al. Ultra fast identification of Aspergillus species in pulmonary cytology specimens by in situ hybridisation. Int J Mol Med 2000;5:427-9.
20. 2 production in healthy subjects. Thromb Res 1980;17:317-27.
21. Patrignani P, Santini G, Panara MR, et al. Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclooxygenase- dependent F2-isoprostane formation. Br J Pharmacol 1996;118:1285-93.
22. Florey CV. Sample size for beginners. BMJ 1993;306:1181-4.
23. Montuschi P, Varone F, Valente S, et al. Methodological aspects of exhaled prostanoid measurements. Eur Respir J 2003;22(Suppl 45):18s.
24. Gavett SH, Madison SL, Chulada PC, et al. Allergic responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 1999;104:721-32.
25. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21.
26. Oguma T, Asano K, Shiomi T, et al. Cyclooxygenase-2 expression during allergic inflammation in guinea-pig lungs. Am J Respir Crit Care Med 2002;165:382-6.
27. Peebles RS Jr, Hashimoto K, Morrow JD, et al. Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 2002;165:1154-60.
28. Peters-Golden M. Open mind, open airways. Broadening the paradigm of prostaglandins and allergic airway inflammation. Am J Respir Crit Care Med 2002;165:1035-6.
29. Effros RM, Hoagland KW, Bosbous M, et al. Dilution of respiratory solutes in exhaled condensates. Am J Respir Crit Care Med 2002;165:663-9.
30. Effros RM, Biller J, Foss B, et al. A simple method for estimating respiratory solute dilution in exhaled breath condensate. Am J Respir Crit Care Med 2003;168:1500-5.
31. Dicpinigaitis PV. Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics. Pulm Pharmacol Ther 2001;14:93-7.